• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Medpace Holdings, Inc. to Report Second Quarter 2025 Financial Results on July 21, 2025

    6/23/25 4:05:00 PM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $MEDP alert in real time by email

    Medpace Holdings, Inc. (NASDAQ:MEDP) ("Medpace") today announced that it will report its second quarter 2025 financial results after the market close on Monday, July 21, 2025. The Company will host a conference call the following morning, Tuesday, July 22, 2025, at 9:00 a.m. ET to discuss these results.

    To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 10 minutes prior to the event start. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique PIN that can be used to access the call.

    To access the conference call via webcast, visit the "Investors" section of Medpace's website at investor.medpace.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.

    A supplemental slide presentation will also be available at the "Investors" section of Medpace's website prior to the start of the call.

    About Medpace

    Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace's mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages regulatory and therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Headquartered in Cincinnati, Ohio, Medpace employs approximately 5,900 people across 44 countries as of March 31, 2025.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250623084622/en/

    Investor Contact:

    Lauren Morris

    513.579.9911 x11994

    [email protected]

    Media Contact:

    Michael Maley

    513.579.9911 x12831

    [email protected]

    Get the next $MEDP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MEDP

    DatePrice TargetRatingAnalyst
    6/24/2025$300.00Equal Weight
    Barclays
    4/22/2025Outperform → Mkt Perform
    William Blair
    4/14/2025$328.00Buy → Hold
    TD Cowen
    3/24/2025$330.00Market Perform
    Leerink Partners
    10/23/2024$413.00 → $349.00Outperform → Neutral
    Robert W. Baird
    10/14/2024Buy
    Redburn Atlantic
    9/27/2024$420.00 → $350.00Buy → Neutral
    UBS
    9/25/2024$415.00 → $345.00Buy → Hold
    Jefferies
    More analyst ratings

    $MEDP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Zander Dani S.

      4 - Medpace Holdings, Inc. (0001668397) (Issuer)

      5/20/25 4:59:16 PM ET
      $MEDP
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 4 filed by Director Mccarthy Cornelius P. Iii

      4 - Medpace Holdings, Inc. (0001668397) (Issuer)

      5/20/25 4:51:25 PM ET
      $MEDP
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 4 filed by Director Kraft Robert O.

      4 - Medpace Holdings, Inc. (0001668397) (Issuer)

      5/20/25 4:45:08 PM ET
      $MEDP
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $MEDP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Barclays initiated coverage on Medpace with a new price target

      Barclays initiated coverage of Medpace with a rating of Equal Weight and set a new price target of $300.00

      6/24/25 8:08:46 AM ET
      $MEDP
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Medpace downgraded by William Blair

      William Blair downgraded Medpace from Outperform to Mkt Perform

      4/22/25 10:17:27 AM ET
      $MEDP
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Medpace downgraded by TD Cowen with a new price target

      TD Cowen downgraded Medpace from Buy to Hold and set a new price target of $328.00

      4/14/25 8:14:21 AM ET
      $MEDP
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care